Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0315576 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift PLOS ONE, 2025. Verfasst von Biban Gill und 12 weiteren Autor:innen. Beteiligte Einrichtung: McMaster Immunology Research Centre and Department of Medicine, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Estrogens, Probiotics, Vagina, Vaginosis, Bacterial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, CIHR HIV Clinical Trials Network.
Abstract (Originalsprache)
Background
A dysbiotic vaginal microbiome (VMB) is associated with clinical conditions such as bacterial vaginosis (BV) and an increased risk of human immunodeficiency virus (HIV-1) infection. Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.
Methods
ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. Feasibility was evaluated through enrolment, retention, and adherence rates, while safety and tolerability were determined by a pre- and post-treatment blood panel and reported adverse events (AEs).
Results
Overall, 63 ACB women were screened, 50 were enrolled and received the intervention while 41 completed the study, resulting in 80% enrollment and 82% retention rates. Overall adherence to the study protocol was high at 93%, with an adherence of 92% for RepHresh™ Pro-B™ and 97% for Estring©. A total of 88 AEs were reported by 29 participants which were mild (66/88; 75%) and largely resolved (82/88;93%) by the end of the study, with no serious AEs (SAEs) noted. In addition, a panel of safety blood markers measured pre- and post-intervention confirmed no clinically significant changes in blood chemistry or blood cell count.
Conclusion
Overall, the administration of intravaginal estrogen and/or probiotics in pre-menopausal ACB women is feasible, safe, and well tolerated.
Trial registration
The trial was registered with Clinicaltrials.gov ( NCT03837015 ) and CIHR HIV Clinical Trials ( CTN308 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- McMaster Immunology Research Centre and Department of Medicine, McMaster University, Hamilton, ON, Canada.
- Afynia Laboratories, Hamilton, ON, Canada.
- Women's Health in Women's Hands Community Health Centre, Toronto, ON, Canada.
- Departments of Microbiology & Immunology and Surgery, Western University, and Canadian Research and Development Centre for Human Microbiome and Probiotics, The Lawson Health Research Institute, London, ON, Canada.
- Departments of Immunology and Medicine, University of Toronto, Toronto, ON, Canada.
- Department of Medicine, University Health Network, Toronto, ON, Canada.
ORCID-Profile: Jenna Ratcliffe, Charu Kaushic
Förderung
- Canadian Institutes of Health Research
- CIHR HIV Clinical Trials Network
Zitieren
APA
Gill, B., Wessels, J. M., Hayes, C. L., Ratcliffe, J., Wokuri, J., Ball, E., Reid, G., Kaul, R., Rana, J., Alkhaifi, M., Tharao, W., Smaill, F., & Kaushic, C. (2025). Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0315576
Vancouver
Gill B, Wessels JM, Hayes CL, Ratcliffe J, Wokuri J, Ball E, et al. Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial. PLOS ONE. 2025. doi:10.1371/journal.pone.0315576
BibTeX
@article{Gill2025,
author = {Gill, Biban and Wessels, Jocelyn M and Hayes, Christina L and Ratcliffe, Jenna and Wokuri, Junic and Ball, Elizabeth and Reid, Gregor and Kaul, Rupert and Rana, Jesleen and Alkhaifi, Muna and Tharao, Wangari and Smaill, Fiona and Kaushic, Charu},
title = {Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0315576}
}
EUVIMED